Tax Partners Malcolm Hochenberg and Richard Corn advise Celgene Corporation on acquisition of Juno Therapeutics
Proskauer represented Celgene Corporation in its definitive agreement to acquire Juno Therapeutics, Inc. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a [...]